Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

randomized controlled trial

  • Home
  • randomized controlled trial
  • Page 2
Efficacy and Safety of ALM-003 Digital Therapeutic in Alcohol Dependence: A Multicenter Open-Label Randomized Controlled Trial
Posted inAI news Psychiatry Specialties

Efficacy and Safety of ALM-003 Digital Therapeutic in Alcohol Dependence: A Multicenter Open-Label Randomized Controlled Trial

Posted by MedXY By MedXY 08/20/2025
This review synthesizes evidence from a multicenter RCT showing ALM-003 digital therapeutic reduces heavy drinking days significantly in alcohol-dependent individuals at high risk, with an excellent safety profile.
Read More
Thoracentesis in Acute Heart Failure: Insights from the TAP-IT Randomized Controlled Trial
Posted inCardiology news Specialties

Thoracentesis in Acute Heart Failure: Insights from the TAP-IT Randomized Controlled Trial

Posted by MedXY By MedXY 08/17/2025
The TAP-IT trial found that additional thoracentesis in acute heart failure patients with pleural effusion did not improve days alive out of hospital, mortality, or length of stay compared to standard therapy alone.
Read More
Examining the Role of Gluten and Wheat in Irritable Bowel Syndrome: Insights from a Double-Blind, Sham-Controlled Crossover Trial
Posted inFamily Medicine & Nutrition Gastroenterology news Specialties

Examining the Role of Gluten and Wheat in Irritable Bowel Syndrome: Insights from a Double-Blind, Sham-Controlled Crossover Trial

Posted by MedXY By MedXY 08/14/2025
A rigorous trial reveals that perceived symptom worsening from gluten or wheat in IBS patients may largely be driven by expectation rather than the substances themselves, underscoring the importance of distinguishing true sensitivities from placebo effects.
Read More
Iloprost in Severe Septic Shock with Persistent Hypoperfusion: Insights from a Rigorous Randomized Trial
Posted inCritical Care news Specialties

Iloprost in Severe Septic Shock with Persistent Hypoperfusion: Insights from a Rigorous Randomized Trial

Posted by MedXY By MedXY 08/13/2025
A recent double-blind RCT shows iloprost did not reduce organ failure severity in septic shock patients with persistent hypoperfusion, highlighting challenges in improving outcomes despite theoretical benefits in microcirculation.
Read More
Mediterranean Diet vs. Australian Guide to Healthy Eating: A Comparison on Body Composition and Glucose Metabolism
Posted inCardiology Family Medicine & Nutrition news Specialties

Mediterranean Diet vs. Australian Guide to Healthy Eating: A Comparison on Body Composition and Glucose Metabolism

Posted by MedXY By MedXY 08/11/2025
This study compares the effects of the Mediterranean diet and the Australian Guide to Healthy Eating (AGHE) on body composition and glucose metabolism, revealing significant benefits of the Mediterranean diet.
Read More
Three Weeks of Ketogenic Diet Significantly Boosts Skeletal Muscle Insulin Sensitivity in Obesity: Insights from a Randomized Crossover Trial
Posted inClinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Three Weeks of Ketogenic Diet Significantly Boosts Skeletal Muscle Insulin Sensitivity in Obesity: Insights from a Randomized Crossover Trial

Posted by MedXY By MedXY 08/08/2025
A 3-week ketogenic diet improved skeletal muscle insulin sensitivity and promoted weight loss in individuals with obesity, without significant effects on liver or adipose tissue insulin sensitivity.
Read More
Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial
Posted inClinical Updates Gastroenterology news Specialties Transplantation

Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial

Posted by MedXY By MedXY 08/07/2025
A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may be crucial.
Read More
Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial
Posted inClinical Updates Gastroenterology news Specialties

Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial

Posted by MedXY By MedXY 08/06/2025
This trial evaluated low-dose hydrocortisone in cirrhotic patients with septic shock, finding no improvement in 28-day mortality or shock resolution compared to placebo.
Read More
Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy
Posted inClinical Updates Hematology-Oncology news Specialties

Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy

Posted by MedXY By MedXY 08/05/2025
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
Read More
Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial
Posted inClinical Updates news Orthopedics Specialties

Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial

Posted by MedXY By MedXY 08/03/2025
The DISTRICTS trial demonstrates that initial surgical treatment for carpal tunnel syndrome leads to significantly higher recovery rates at 18 months compared to starting with corticosteroid injections, despite similar adverse event profiles.
Read More
Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

Posted by MedXY By MedXY 08/02/2025
The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.
Read More
Pramipexole Augmentation in Treatment-Resistant Unipolar Depression: A UK Multicentre Randomised Trial
Posted inClinical Updates news Psychiatry Specialties

Pramipexole Augmentation in Treatment-Resistant Unipolar Depression: A UK Multicentre Randomised Trial

Posted by MedXY By MedXY 08/02/2025
A UK multicentre, double-blind, placebo-controlled trial demonstrates that pramipexole augmentation at 2.5 mg reduces depressive symptoms in treatment-resistant unipolar depression at 12 weeks, with some adverse effects noted, supporting its clinical utility.
Read More

Posts pagination

Previous page 1 2
  • Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT
  • Cardiomyopathy Gene Therapy Reaches an Inflection Point: From AAV Delivery to Precision Genome Editing
  • Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
  • Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury
  • Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in